| Publications | PubMed=1067619; DOI=10.1073/pnas.73.9.3278; PMCID=PMC431008
Thomas E. Carey, Toshitada Takahashi, Lois A. Resnick-Silverman, Herbert Friedrich Oettgen, Lloyd John Old;
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976) PubMed=327080; DOI=10.1093/jnci/59.1.221
Jorgen Fogh, Jens M. Fogh, Thomas Orfeo;
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977) PubMed=6933476; DOI=10.1073/pnas.77.7.4260; PMCID=PMC349812
Alan N. Houghton, Michael C. Taormina, Hisami Ikeda, Tadashi Watanabe, Herbert Friedrich Oettgen, Lloyd John Old;
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980) DOI=10.1007/978-1-4615-7228-2_39
Alan N. Houghton, Herbert Friedrich Oettgen, Lloyd John Old;
Malignant melanoma. Current status of the search for melanoma-specific antigens.
(In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai, Bijan & Good, Robert Alan (eds.); pp.557-576; Springer; Boston; USA (1981) PubMed=6197381; DOI=10.1002/ijc.2910320610
Michael Jules Mattes, Timothy M. Thomson, Lloyd John Old, Kenneth Oliver Lloyd;
A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum.
Int. J. Cancer 32:717-721(1983) PubMed=6864164; DOI=10.1084/jem.158.1.53; PMCID=PMC2187084
Alan N. Houghton, Hannah Brooks, Richard J. Cote, Michael C. Taormina, Herbert Friedrich Oettgen, Lloyd John Old;
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
J. Exp. Med. 158:53-65(1983) Patent=US4591572
Michael Jules Mattes, Timothy M. Thomson, Lloyd John Old, Kenneth Oliver Lloyd;
Pigmentation associated, differentiation antigen of human melanoma and autologous antibody.
Patent number US4591572, 27-May-1986 PubMed=3518877; DOI=10.3109/07357908609038260
Jorgen Fogh;
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986) PubMed=7747814; PMCID=PMC1869278
Nelleke A. Gruis, Jane M. Weaver-Feldhaus, Qing-Yun Liu, Cheryl Frye, Rosalind Eeles, Irene Orlow, Louis Lacombe, Veronica Ponce-Castaneda, Pilar Lianes, Esther Latres, Mark Henry Skolnick ...Show all 13 authors... , Carlos Cordon-Cardo, Alexander Kamb; Show fewer authors
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.
Am. J. Pathol. 146:1199-1206(1995) PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Graeme J. Walker, Jose F. Flores, J. Michael Glendening, Amy Hsiu-Ti Lin, Isabel D.C. Markl, Jane W. Fountain;
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998) PubMed=21725359; DOI=10.1038/onc.2011.250; PMCID=PMC3267014
Feng Xing, Yogindra Persaud, Christine A. Pratilas, Barry Stephen Taylor, Manickam Janakiraman, Qing-Bai She, Humilidad F. Gallardo, C. Liu, Taha Merghoub, Blake E. Hefter, Igor Dolgalev ...Show all 19 authors... , Agnes J. Viale, Adriana Heguy, Elisa de Stanchina, David Cobrinik, Gideon Bollag, Jedd D. Wolchok, Alan N. Houghton, David B. Solit; Show fewer authors
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Oncogene 31:446-457(2012) PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625; PMCID=PMC4005042
Moriah Heller Nissan, Christine A. Pratilas, Alexis M. Jones, Ricardo Ramirez, Helen Won, Cai-Lian Liu, Shakuntala Tiwari, Li Kong, Aphrothiti J. Hanrahan, Zhan Yao, Taha Merghoub ...Show all 19 authors... , Antoni Ribas, Paul B. Chapman, Rona D. Yaeger, Barry Stephen Taylor, Nikolaus Schultz, Michael F. Berger, Neal Rosen, David B. Solit; Show fewer authors
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Cancer Res. 74:2340-2350(2014) |
|---|
